Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human dose-escalation study of enapotamab vedotin in advanced solid tumors
NL-OMON48742Phase 2Not yet recruiting
- Sponsor
- Genmab
- Start
- Apr 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enapotamab vedotin in Nonhematologic neoplasms, sponsored by Genmab. Primary endpoints: Dose-limiting toxicities and Safety profile. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
enapotamab vedotin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON48742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48742.